Cargando…

Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma

We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multip...

Descripción completa

Detalles Bibliográficos
Autores principales: Terao, Toshiki, Yamashita, Takeshi, Fukumoto, Ami, Kamura, Yuya, Ikeda, Daisuke, Kuzume, Ayumi, Tabata, Rikako, Tsushima, Takafumi, Miura, Daisuke, Narita, Kentaro, Takeuchi, Masami, Doi, Masahiro, Umezawa, Yuka, Otsuka, Yoshihito, Takamatsu, Hiroyuki, Matsue, Kosei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860256/
https://www.ncbi.nlm.nih.gov/pubmed/35190963
http://dx.doi.org/10.1007/s12185-022-03300-4
_version_ 1784654631183319040
author Terao, Toshiki
Yamashita, Takeshi
Fukumoto, Ami
Kamura, Yuya
Ikeda, Daisuke
Kuzume, Ayumi
Tabata, Rikako
Tsushima, Takafumi
Miura, Daisuke
Narita, Kentaro
Takeuchi, Masami
Doi, Masahiro
Umezawa, Yuka
Otsuka, Yoshihito
Takamatsu, Hiroyuki
Matsue, Kosei
author_facet Terao, Toshiki
Yamashita, Takeshi
Fukumoto, Ami
Kamura, Yuya
Ikeda, Daisuke
Kuzume, Ayumi
Tabata, Rikako
Tsushima, Takafumi
Miura, Daisuke
Narita, Kentaro
Takeuchi, Masami
Doi, Masahiro
Umezawa, Yuka
Otsuka, Yoshihito
Takamatsu, Hiroyuki
Matsue, Kosei
author_sort Terao, Toshiki
collection PubMed
description We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multiple myeloma (MM)] were evaluated. Seropositivity was observed in 88.7% and a clinically protective titer in 38.3% of MM patients, both of which were significantly lower than those of healthy controls. Patients receiving anti-CD38 antibodies had much lower antibody titers, but antibody titers recovered in those who underwent a wash-out period before vaccine administration. Older age (≥65), anti-CD38 antibody administration, immunomodulatory drugs use, lymphopenia (<1000/μL), and lower polyclonal IgG (<550 mg/dL) had a negative impact for the sufficient antibody production according to multivariate analysis. Patients with clinically protective titer had a significantly higher number of CD19+ lymphocytes than those with lower antibody responses (114 vs. 35/μL, p = 0.016). Our results suggested that patients with PCD should be vaccinated, and that the ideal protocol is to temporarily interrupt anti-CD38 antibody therapy for a “wash-out” period of a few months, followed by a (booster) vaccine after the B-cells have recovery. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12185-022-03300-4.
format Online
Article
Text
id pubmed-8860256
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-88602562022-02-22 Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma Terao, Toshiki Yamashita, Takeshi Fukumoto, Ami Kamura, Yuya Ikeda, Daisuke Kuzume, Ayumi Tabata, Rikako Tsushima, Takafumi Miura, Daisuke Narita, Kentaro Takeuchi, Masami Doi, Masahiro Umezawa, Yuka Otsuka, Yoshihito Takamatsu, Hiroyuki Matsue, Kosei Int J Hematol Original Article We conducted a prospective, three-center, observational study in Japan to evaluate the prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 vaccination in patients with plasma cell dyscrasia(PCD). Two-hundred sixty-nine patients with PCD [206 symptomatic multiple myeloma (MM)] were evaluated. Seropositivity was observed in 88.7% and a clinically protective titer in 38.3% of MM patients, both of which were significantly lower than those of healthy controls. Patients receiving anti-CD38 antibodies had much lower antibody titers, but antibody titers recovered in those who underwent a wash-out period before vaccine administration. Older age (≥65), anti-CD38 antibody administration, immunomodulatory drugs use, lymphopenia (<1000/μL), and lower polyclonal IgG (<550 mg/dL) had a negative impact for the sufficient antibody production according to multivariate analysis. Patients with clinically protective titer had a significantly higher number of CD19+ lymphocytes than those with lower antibody responses (114 vs. 35/μL, p = 0.016). Our results suggested that patients with PCD should be vaccinated, and that the ideal protocol is to temporarily interrupt anti-CD38 antibody therapy for a “wash-out” period of a few months, followed by a (booster) vaccine after the B-cells have recovery. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12185-022-03300-4. Springer Nature Singapore 2022-02-21 2022 /pmc/articles/PMC8860256/ /pubmed/35190963 http://dx.doi.org/10.1007/s12185-022-03300-4 Text en © Japanese Society of Hematology 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Terao, Toshiki
Yamashita, Takeshi
Fukumoto, Ami
Kamura, Yuya
Ikeda, Daisuke
Kuzume, Ayumi
Tabata, Rikako
Tsushima, Takafumi
Miura, Daisuke
Narita, Kentaro
Takeuchi, Masami
Doi, Masahiro
Umezawa, Yuka
Otsuka, Yoshihito
Takamatsu, Hiroyuki
Matsue, Kosei
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
title Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
title_full Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
title_fullStr Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
title_full_unstemmed Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
title_short Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
title_sort low clinical protective response to sars-cov-2 mrna covid-19 vaccine in patients with multiple myeloma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860256/
https://www.ncbi.nlm.nih.gov/pubmed/35190963
http://dx.doi.org/10.1007/s12185-022-03300-4
work_keys_str_mv AT teraotoshiki lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT yamashitatakeshi lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT fukumotoami lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT kamurayuya lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT ikedadaisuke lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT kuzumeayumi lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT tabatarikako lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT tsushimatakafumi lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT miuradaisuke lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT naritakentaro lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT takeuchimasami lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT doimasahiro lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT umezawayuka lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT otsukayoshihito lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT takamatsuhiroyuki lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma
AT matsuekosei lowclinicalprotectiveresponsetosarscov2mrnacovid19vaccineinpatientswithmultiplemyeloma